- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03148808
Natural Vascular Scaffold (NVS) Therapy
Natural Vascular Scaffold (NVS) Therapy for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a prospective, non-randomized, multi-center, open label Phase 1 study to assess the safety, pharmacokinetics (PK), and preliminary efficacy trends of applying NVS Therapy to de novo lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) during percutaneous transluminal angioplasty (PTA) in patients with life-style limiting claudication due to obstructive SFA and proximal popliteal artery atherosclerosis. Each investigator will receive supervised training for each procedure.
Eligibility to participate in the study is determined during the screening period and prior to the index procedure. Once a subject has been determined to be suitable for a peripheral intervention and all general eligibility criteria are met, angiographic eligibility will be evaluated at the time of the index procedure. Subjects then undergo the procedure with the NVS Therapy. Study data will be analyzed through the Day 365 follow-up visit.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43214
- OhioHealth Research Institute
-
-
Pennsylvania
-
Wynnewood, Pennsylvania, United States, 19096
- Lankenau Institute for Medical Research
-
-
Tennessee
-
Kingsport, Tennessee, United States, 37660
- Wellmont CVA Heart Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is at least 18 years of age.
- Subject (or legal guardian) understands the study requirements and the treatment procedure and provides written informed consent before any study-specific tests or procedures are performed.
- Subject is eligible for PTA.
- Subject is willing to comply with all protocol required follow-up evaluations.
- Subject has documented Rutherford Classification 2 to 4 (see Appendix 3).
- Subject has laboratory test results that are within clinically acceptable limits.
- In Investigator's opinion, subject is hemodynamically stable at the time of the index procedure.
- Subject has a life expectancy of ≥1 year in the opinion of the Investigator.
Exclusion Criteria:
- Subject had cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 3 months prior to enrollment.
- Subject has any permanent neurologic defect that may cause non-compliance with the protocol.
- Subject had an MI within last the 3 months prior to enrollment.
- Subject is pregnant, planning to become pregnant, breastfeeding or planning to breastfeed in the next 365 days.
- Subject is currently receiving oral or intravenous immunosuppressive therapy (ie, inhaled steroids are not excluded).
- Subject has known life-limiting immunosuppressive or autoimmune disease (eg, human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus).
- Subject has local or systemic thrombolytic therapy within 48 hours prior to index procedure.
- Subject is currently on oral anticoagulation therapy, such as warfarin, rivaroxaban, apixaban, or dabigatran etexilate.
- Subject has known allergies or sensitivities to heparin, aspirin (ASA), or other anticoagulant/antiplatelet therapies.
- Subject has an allergy to contrast media that cannot be adequately pre-treated prior to the index procedure.
- Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding.
- Subject has documented or suspected liver disease, including laboratory evidence of hepatitis.
- Subject has renal failure or chronic kidney disease with glomerular filtration rate (GFR) ≤ 30 mL/min or Modification of Diet in Renal Disease (MDRD) study equation result of ≤ 30 mL/min per 1.73 m2.
- Subject has white blood cell (WBC) count < (3,000 cells/mm3) within 7 days prior to index procedure.
- Subject has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3 ≤ 7 days pre-procedure.
- Subject has been diagnosed with bleeding diatheses or hypercoagulable state.
- Subject has known or suspected active systemic infection evidenced by WBC > 14.0 (14,000/mm3).
- Subject is currently participating in another investigational drug or device study.
- Subject intends to participate in another investigational drug or device study within 365 days after the index procedure.
- Subject has any surgical procedure or intervention performed within the 30-day period prior to index procedure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NVS Therapy
NVS Therapy will be delivered to de novo lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
|
Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS Light Fiber, and NVS Light Source.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from all-cause mortality, target limb major amputation, and target lesion revascularization based on clinical observations
Time Frame: Day 30
|
The overall composite occurrence of participants free from from all-cause mortality, target limb major amputation, and target lesion revascularization through post-index procedure to Day 30 will be summarized as a percentage.
|
Day 30
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NVS Drug Plasma Concentrations
Time Frame: Day 1
|
The Peak Plasma Concentration (Cmax) will be determined from plasma 10-8-10 Dimer concentrations for blood samples collected.
|
Day 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gary Ansel, MD, OhioHealth Research Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Protocol No.: 1060-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on NVS Therapy
-
Alucent BiomedicalCompletedPeripheral Arterial Disease | Peripheral Vascular Diseases | Catheterization, PeripheralUnited States
-
Vegenat, S.A.UnknownHyperglycemia | Metabolic Syndrome | DiabeticsSpain
-
University of Alabama at BirminghamCompleted
-
Mennallah Ahmed Mohamed Anwar ElgendyNot yet recruiting
-
Spaulding Rehabilitation HospitalActive, not recruiting
-
Istanbul Medipol University HospitalCompleted
-
St. Jude Children's Research HospitalCompletedStem Cell Transplant | Bone MarrowUnited States, Canada
-
Universidad de ZaragozaCompletedPlagiocephaly | Plagiocephaly, Nonsynostotic | Plagiocephaly, PositionalSpain
-
National Taiwan University HospitalNot yet recruitingAutism | Language Delay | Speech Disorders in Children